Mallinckrodt plc ("Mallinckrodt") and Endo, Inc. (OTCQX: NDOI) ("Endo") today reported significant progress toward their proposed merger to create a global, scaled, diversified therapeutics leader.

Endo Inc (NDOI) reports a mixed quarter with revenue challenges in key segments but remains optimistic about future growth through strategic product launches and mergers.

Malvern-based Endo has approved $3.5 million in retention bonuses for its key executives as it works toward a merger with ...

Endo Inc.'s first quarter 2025 financial results ... We had a number of moving pieces during the quarter, including our announced merger with Mallinckrodt and the divestiture of International ...

Endo, Inc. (OTCQX: NDOI)’s merger with Mallinckrodt plc. Under the terms of the proposed transaction, Endo shareholders will receive a total of $80 million in cash (subject to possible ...

If you are an Avalon shareholder, click here to learn more about your rights and options. Endo, Inc. (OTCQX: NDOI)’s merger with Mallinckrodt plc. Under the terms of the proposed ...

Mr. Olafsson added, "Our team has made excellent progress toward completing our merger with Endo to create a global, scaled, diversified pharmaceuticals leader, which we expect to occur in the ...

Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today reported its financial results for the first quarter ended March 28, ...